Swiss medtech company Medartis is reportedly planning to expand into the U.S. market and continue investing in Germany with the funds from its recently-announced initial public offering. Medartis announced yesterday that its IPO could include up to 2.84 million new shares of common stock priced at 44 – 54 [...]
ZURICH, Feb 27 (Reuters) – Medartis Holding AG, a medical device maker specializing in surgical bone repairs, plans to sell shares in an initial public offering (IPO) on the SIX Swiss Exchange in the first half of 2018, it said on Tuesday. Medartis, whose products are sold in 44 [...]
The Myeloid Solution by SOPHiA GENETICS is the best-in-class molecular diagnostic application which empowers clinicians to more precisely diagnose hematological disorders Lausanne, SWITZERLAND – 06th February 2018: SOPHiA GENETICS, global leader in Data-Driven Medicine, unveiled today the world’s first capture-based myeloid clinical solution to receive the CE-IVD mark. The [...]
Results highlight robust Sonata System design and its potential to become a standard of care for fibroid treatment REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the results from their pivotal IDE trial for the [...]
Endeavour Vision invested in Medartis. Located in Basel, Switzerland, the company develops, manufactures and distributes medical internal fixation devices and surgical instruments offered in system solutions for small bone fractures focusing on the extremities. Medartis was founded in 1997 by Dr. Thomas Straumann. The company launched its first products [...]
Novel uterus-preserving Sonata System is first incision-free treatment to address majority of fibroids transcervically REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for uterine fibroids, today announced its submission to the FDA of its 510(k) Premarket Notification for the Sonata® System, [...]
ST. PAUL, Minn., Oct. 23, 2017 /PRNewswire/ — EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the Company has formally changed its name to ReShape Lifesciences Inc. (NASDAQ: RSLS). The new name, effective today, reflects the Company’s expansion [...]
EnteroMedics Announces Acquisition Of ReShape Medical Acquisition Adds Approved, Revenue-Generating Balloon Technology for Obesity ST. PAUL, Minn., Oct. 3, 2017 /PRNewswire/ — EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has acquired ReShape [...]
VentureMed Group Raises $15 Million Series B Equity Financing TOLEDO, Ohio, Aug. 15, 2017 /PRNewswire/ — VentureMed Group®, Inc., (“VMG” or the “Company”) a medical device company developing and commercializing next-generation endovascular products to treat patients suffering from peripheral artery disease (PAD), today announced it had raised $15 [...]
Zurich-Schlieren, May 30, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the first patient was dosed in the phase 2 multiple myeloma study of its lead oncology asset MP0250. In the first phase 2 [...]